<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047734</url>
  </required_header>
  <id_info>
    <org_study_id>RPC01-201-PartB</org_study_id>
    <secondary_id>2012-002714-40</secondary_id>
    <nct_id>NCT02047734</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis</brief_title>
  <acronym>RADIANCE</acronym>
  <official_title>A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented&#xD;
      within this record.&#xD;
&#xD;
      The primary objective of Part B is to assess whether the clinical efficacy of ozanimod&#xD;
      (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of&#xD;
      clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial (RPC01-201; RADIANCE) consisted of 2 parts, each reported separately on&#xD;
      ClinicalTrials.gov: Part A (NCT01628393) and Part B (this record).&#xD;
&#xD;
      Part A was a phase 2 study in which two doses of ozanimod were administered daily for 24&#xD;
      weeks with an efficacy and safety comparison to a placebo control and is reported separately&#xD;
      as ClinicalTrials.gov record NCT01628393.&#xD;
&#xD;
      Part B, reported herein, was a phase 3 study in which two doses of ozanimod were administered&#xD;
      daily for a 24 month period compared to an active control, interferon β-1a. Participants were&#xD;
      allowed to enroll in the open-label extension study RPC01-3001 (NCT02576717) or complete the&#xD;
      study with a safety follow-up visit 28 days after their last dose of study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2013</start_date>
  <completion_date type="Actual">April 13, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Annualized Relapse Rate (ARR) at the End of Month 24</measure>
    <time_frame>At the end of month 24</time_frame>
    <description>A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for &gt; 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.&#xD;
Relapse rate was calculated as the total number of confirmed relapses divided by the total number of days in the study * 365.25.&#xD;
ARR was based on a Poisson regression model, adjusted for region (Eastern Europe vs Rest of the World), age, and the Baseline number of gadolinium-enhancing lesions, and included the natural log transformation of time on study as an offset term.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 24 Months</measure>
    <time_frame>24 month treatment period; MRI scans were performed at Months 12 and 24</time_frame>
    <description>The adjusted mean number of new or enlarging hyperintense T2-weighted brain MRI lesions per scan was based on the cumulative number of new or enlarging T2 lesions since Baseline over 24 months. MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.&#xD;
The adjusted mean per scan over 24 months was based based on a negative binomial regression model using observed data, adjusted for region (Eastern Europe vs. Rest of the World), age at Baseline, and Baseline number of GdE lesions. The natural log transformation of the number of available MRI scans over 24 months is used as an offset term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Number of Gadolinium Enhancing Brain Lesions at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.&#xD;
The number of gadolinium-enhancing (GdE) lesions at 24 months was analyzed based on observed data using a negative binomial regression model adjusted for region (Eastern Europe vs Rest of World), Baseline age, and Baseline number of GdE lesions, with natural log transformation of number of available MRI scans over 24 months as an offset term (1 scan for per participant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Disability Progression Confirmed After 3 Months</measure>
    <time_frame>From first dose to the end of the 24-month treatment period</time_frame>
    <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Disability Progression Confirmed After 6 Months</measure>
    <time_frame>From first dose to the end of the 24-month treatment period</time_frame>
    <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Gadolinium Enhancing (GdE) Lesion-Free at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Participants were considered lesion free at Month 24 if they did not show evidence of GdE lesions at the Month 24 MRI scan.&#xD;
MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were New or Enlarging T2 Lesion-Free at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Normalized Brain Volume to Month 24</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Brain volume (a measure of brain atrophy) was measured by brain MRI scans that were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 24 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>The MSFC-LCLA is a battery including the following 4 individual scales:&#xD;
Timed 25-Foot Walk is an ambulation measure of walking 25 feet with time taken recorded in seconds&#xD;
9-Hole Peg Test (9HPT) is a quantitative measure of upper extremity (arm and hand) function&#xD;
Symbol Digit Modalities Test (SDMT) is a measure of executive cognitive function that assesses processing speed, flexibility, and calculation ability&#xD;
Low-Contrast Letter Acuity Test (LCLA) used a standardized set of charts to assess low contrast visual acuity, charts are scored according to the number of letters that are identified correctly&#xD;
Z-scores were calculated for for each component and averaged to create an overall composite score, using the study population as the reference population. A Z-score represents the number of standard deviations a patient's test result is higher (Z &gt; 0) or lower (Z &lt; 0) than the average test result (Z = 0) of the reference population. A positive change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>The MSQOL-54 is a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. The instrument includes 12 subscales, two summary scores, and two single-item measures.&#xD;
The two summary scores - physical health and mental health - are derived from a weighted combination of scale scores.&#xD;
The physical health composite score includes Physical function, Health perceptions, Energy/fatigue, Role limitations - physical, Pain, Sexual function, Social function, and Health distress.&#xD;
The mental health composite score includes Health distress, Overall quality of life, Emotional well-being, Role limitations - emotional, and Cognitive function.&#xD;
Each composite summary score has a range from 0 to 100 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From the first dose of study drug up to the first dose of the open-label extension study RPC01-3001, or up to 28 days after last dose for participants who did not continue into the open-label extension study; median duration of treatment was 24 months.</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP), including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes.&#xD;
The investigator assessed the severity of AEs as mild, moderate, or severe and the relationship of each AE to treatment as unrelated, unlikely, possible, probable, or related based on timing and other known factors such as clinical state, environment, or other therapies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1320</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Ozanimod 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozanimod1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon β-1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>Oral capsule, daily for 24 months</description>
    <arm_group_label>Ozanimod 0.5 mg</arm_group_label>
    <arm_group_label>Ozanimod1 mg</arm_group_label>
    <other_name>RPC1063</other_name>
    <other_name>Zeposia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod placebo</intervention_name>
    <description>Oral capsule, daily for 24 months</description>
    <arm_group_label>Interferon β-1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Intramuscular injection, 30 µg, weekly for 24 months</description>
    <arm_group_label>Interferon β-1a</arm_group_label>
    <other_name>Avonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a placebo</intervention_name>
    <description>Intramuscular injection, weekly for 24 months</description>
    <arm_group_label>Ozanimod 0.5 mg</arm_group_label>
    <arm_group_label>Ozanimod1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary progressive multiple sclerosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Receptos Study Site 115</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 118</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Josephs Hosptial and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Territory Neurology and Research Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 119</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 110</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 122</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 112</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center at UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 120</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Neurological Research LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 127</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates PA</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 114</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 124</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies Inc</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 123</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Georgia Sleep Disorder Center and Neurology Associates</name>
      <address>
        <city>Douglasville</city>
        <state>Georgia</state>
        <zip>30134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants In Neurology</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 113</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 121</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 101</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurological Institute PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neuroscience Associates Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 107</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 104</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 109</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 102</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Polyclinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 125</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital</name>
      <address>
        <city>Gomel</city>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 904</name>
      <address>
        <city>Gomel</city>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grodno Clinical Regional Hospital</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 907</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Municipal Clinical Hospital 5</name>
      <address>
        <city>Minsk</city>
        <zip>220026</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 902</name>
      <address>
        <city>Minsk</city>
        <zip>220026</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 901</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre of Neurology and Neurosurgery</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk City Clinical Hospital 9</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 903</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 905</name>
      <address>
        <city>Vitebsk</city>
        <zip>210023</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Diagnostic Centre</name>
      <address>
        <city>Vitebsk</city>
        <zip>210023</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 906</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 256</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 255</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Chretien Clinique Saint Joseph</name>
      <address>
        <city>Montegnee</city>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 252</name>
      <address>
        <city>Montegnée</city>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Pierre</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 254</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 911</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 453</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 454</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 452</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 456</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 457</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Aleksandrovska EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 451</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 455</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta MS Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 154</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 923</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 921</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 922</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 924</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Sestre milosrdnice&quot;, Clinic of Internal Diseases</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sveti duh</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 301</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD MediClubGeorgia</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 302</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 303</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarajishvili Institute of Neurology</name>
      <address>
        <city>Tbilisi</city>
        <zip>112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evaggelismos General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 552</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 554</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navy Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 553</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 551</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHEPA University General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 557</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgios Papanikolaou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 555</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 352</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc DelPesti Korhaz es Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 356</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 354</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaszary Kolos Korhaz</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 358</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SzabolcsSzatmarBereg Megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 351</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 355</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 654</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto San Raffaele G Giglio di Cefalu</name>
      <address>
        <city>Cefalu</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 653</name>
      <address>
        <city>Cefalù</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 655</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 652</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Montichiari</name>
      <address>
        <city>Montichiari</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 659</name>
      <address>
        <city>Montichiari</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 656</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 658</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 651</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 657</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Institutul de Medicina Urgenta</name>
      <address>
        <city>Chisinau</city>
        <zip>2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 932</name>
      <address>
        <city>Chisinau</city>
        <zip>2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Neurologie si Neurochirurgie</name>
      <address>
        <city>Chisinau</city>
        <zip>2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 931</name>
      <address>
        <city>Chisinau</city>
        <zip>2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 933</name>
      <address>
        <city>Chisinau</city>
        <zip>2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 401</name>
      <address>
        <city>Bialystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 423</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-654</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Lek Med Robert Bonek</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-654</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi</name>
      <address>
        <city>Czeladz</city>
        <zip>41-250</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 406</name>
      <address>
        <city>Czeladz</city>
        <zip>41-250</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 405</name>
      <address>
        <city>Gdansk</city>
        <zip>80-083</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 425</name>
      <address>
        <city>Gdansk</city>
        <zip>80-299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copernicus PL Sp. z. o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROMEDIC Janusz Zbrojkiewicz</name>
      <address>
        <city>Katowice</city>
        <zip>40-555</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MA LEK AM Maciejowscy SC Centrum Terapii SM</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 427</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NovoMed Zielinski i Wspolnicy Spolka Jawna</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 426</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROCARE Site Management Organization Gabriela KlodowskaDuda</name>
      <address>
        <city>Katowice</city>
        <zip>40-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 407</name>
      <address>
        <city>Katowice</city>
        <zip>40-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 417</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 424</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RESMEDICA Spolka z o.o.</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny</name>
      <address>
        <city>Konstancin Jeziorna</city>
        <zip>05-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 404</name>
      <address>
        <city>Konstancin-Jeziorna</city>
        <zip>05-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp. z. o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 414</name>
      <address>
        <city>Krakow</city>
        <zip>31-305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Krzysztof Selmaj</name>
      <address>
        <city>Lodz</city>
        <zip>93-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 411</name>
      <address>
        <city>Lodz</city>
        <zip>93-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 412</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 420</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 402</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-443</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 415</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska</name>
      <address>
        <city>Plewiska</city>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 421</name>
      <address>
        <city>Plewiska</city>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej KENDRON</name>
      <address>
        <city>Podlaskie</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak</name>
      <address>
        <city>Pomorskie</city>
        <zip>80-299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 408</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im HSwiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 418</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EUROMEDIS Sp. z.o.o.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 419</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski</name>
      <address>
        <city>Warminsko-mazurskie</city>
        <zip>10-443</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Warsaw</city>
        <zip>00-739</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 410</name>
      <address>
        <city>Warszawa</city>
        <zip>00-739</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne NeuroProtect</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 428</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSW w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 422</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 403</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 413</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital of Psychiatry and Neurology Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 503</name>
      <address>
        <city>Brasov</city>
        <zip>500123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Club Medical Center S.R.L.</name>
      <address>
        <city>Campulung</city>
        <zip>115100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 502</name>
      <address>
        <city>Campulung</city>
        <zip>115100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 501</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Clinical Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 505</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibiu Emergency County Clinical Hospital</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 506</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timisoara Emergency County Clinical Hospital</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk City Clinical Hospital 3</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 701</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 704</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital for Rehabilitation Treatment</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 713</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Complex Vashe Zdorovie</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital 2 na NA Semashko OAO RZhD</name>
      <address>
        <city>Moscow</city>
        <zip>107150</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 712</name>
      <address>
        <city>Moscow</city>
        <zip>107150</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 1 na NIPirogov</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 709</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City neurology center Sibneuromed LLC</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 703</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm State Medical Academy</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 710</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 716</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Hospital named after MI Kalinin</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 4</name>
      <address>
        <city>Saransk</city>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 715</name>
      <address>
        <city>Saransk</city>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 714</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 707</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 708</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Medical Military Academy na SMKirov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 717</name>
      <address>
        <city>Tyumen</city>
        <zip>625000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neftyanik Medical and Sanitary Unit</name>
      <address>
        <city>Tyumen</city>
        <zip>625048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 711</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Clinical Hospital 8</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centar Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 602</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 603</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 604</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 601</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 605</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bratislava - Hospital ak. L. Derera, II Neurology Clinic</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 946</name>
      <address>
        <city>Bratislava</city>
        <zip>83305</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 942</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 945</name>
      <address>
        <city>Trnava</city>
        <zip>917 75</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 956</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4321</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Practice</name>
      <address>
        <city>Pretoria</city>
        <zip>0040</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 953</name>
      <address>
        <city>Pretoria</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 755</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 763</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Canarias</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 756</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 760</name>
      <address>
        <city>Girona</city>
        <state>Cataluña</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 762</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 752</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 761</name>
      <address>
        <city>Bilbao</city>
        <state>País Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 759</name>
      <address>
        <city>San Sebastián</city>
        <state>País Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 758</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Sanitaria Integrada Bilbao Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 757</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 751</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 754</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vírgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Medical &amp; Preventive Institution Chernigiv Regional Clinical Hospital</name>
      <address>
        <city>Chernigiv</city>
        <zip>14033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 805</name>
      <address>
        <city>Chernihiv</city>
        <zip>14033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Chernivtsi Regional Psychiatric Hospital</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 813</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 802</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 815</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49095</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Ivano Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 801</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 814</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Kherson City Clinical Hospital</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 811</name>
      <address>
        <city>Kherson</city>
        <zip>73003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 818</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 803</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital 4</name>
      <address>
        <city>Kyiv</city>
        <zip>3110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Lutsk City Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 816</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 817</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 812</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU</name>
      <address>
        <city>Odesa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 810</name>
      <address>
        <city>Odesa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Odesa Regional Clinical Hospital</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 804</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 809</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Clinical Hospital 6</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 806</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton East Sussex</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 965</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 963</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 961</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 967</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 966</name>
      <address>
        <city>Romford</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Receptos Study Site 964</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cree B, et al. The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics. Presented at the 69th Annual American Academy of Neurology Meeting, April 22-28, 2017, Boston, MA. Abstract No. P6-344</citation>
  </results_reference>
  <results_reference>
    <citation>Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.</citation>
    <PMID>31492652</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2014</study_first_submitted>
  <study_first_submitted_qc>January 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2021</results_first_posted>
  <disposition_first_submitted>April 4, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 4, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 6, 2018</disposition_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Ozanimod</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 4, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02047734/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02047734/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 147 academic medical centers and clinical practices in 21 countries in North America, Europe, and South Africa. Between December 2013 and March 2015, 1695 participants were screened, of which 375 did not meet inclusion criteria. One thousand, three hundred and twenty participants with relapsing multiple sclerosis (MS) were enrolled and randomly assigned to a treatment group.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1:1 ratio to one of three treatment groups. Randomization was stratified by Baseline Expanded Disability Status Scale (EDSS) score (≤ 3.5, &gt; 3.5) and by country.&#xD;
Participants who completed the 24-month study were eligible to enroll in a long-term, open-label extension study (RPC01-3001; NCT02576717).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interferon Beta-1a (IFN β-1a)</title>
          <description>Participants received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Ozanimod 0.5 mg</title>
          <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
        </group>
        <group group_id="P3">
          <title>Ozanimod 1 mg</title>
          <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
                <participants group_id="P2" count="443"/>
                <participants group_id="P3" count="434"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="441">One participant received ozanimod 0.5 mg in error</participants>
                <participants group_id="P2" count="439">One participant received ozanimod 1.0 mg in error</participants>
                <participants group_id="P3" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="376"/>
                <participants group_id="P2" count="374"/>
                <participants group_id="P3" count="388"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of study drug; participants were analyzed according to the treatment they were randomized to receive and not according to what they actually received, if different.</population>
      <group_list>
        <group group_id="B1">
          <title>Interferon Beta-1a (IFN β-1a)</title>
          <description>Participants received IFN β-1a 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Ozanimod 0.5 mg</title>
          <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Ozanimod 1 mg</title>
          <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="441"/>
            <count group_id="B2" value="439"/>
            <count group_id="B3" value="433"/>
            <count group_id="B4" value="1313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="9.07"/>
                    <measurement group_id="B2" value="35.4" spread="8.82"/>
                    <measurement group_id="B3" value="36.0" spread="8.89"/>
                    <measurement group_id="B4" value="35.5" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="291"/>
                    <measurement group_id="B4" value="882"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="436"/>
                    <measurement group_id="B2" value="433"/>
                    <measurement group_id="B3" value="423"/>
                    <measurement group_id="B4" value="1292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="428"/>
                    <measurement group_id="B4" value="1291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Western Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="374"/>
                    <measurement group_id="B4" value="1131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Southern Africa</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Country of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Belarus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Belgium</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bosnia And Herzegovina</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bulgaria</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Canada</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Croatia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Georgia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greece</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hungary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Italy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poland</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Republic of Moldova</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Romania</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Russian Federation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Serbia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slovakia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South Africa</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Spain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ukraine</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>United Kingdom</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>United States</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Multiple Sclerosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Relapsing-remitting multiple sclerosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="432"/>
                    <measurement group_id="B3" value="425"/>
                    <measurement group_id="B4" value="1289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive-relapsing multiple sclerosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Secondary progressive multiple sclerosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at MS Symptom Onset</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="8.60"/>
                    <measurement group_id="B2" value="29.3" spread="8.41"/>
                    <measurement group_id="B3" value="29.2" spread="8.67"/>
                    <measurement group_id="B4" value="29.1" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at MS Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="8.82"/>
                    <measurement group_id="B2" value="32.0" spread="8.59"/>
                    <measurement group_id="B3" value="32.1" spread="8.95"/>
                    <measurement group_id="B4" value="31.9" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since MS Symptom Onset</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.36" spread="6.065"/>
                    <measurement group_id="B2" value="6.23" spread="5.547"/>
                    <measurement group_id="B3" value="6.92" spread="6.201"/>
                    <measurement group_id="B4" value="6.50" spread="5.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS) Score</title>
          <description>The EDSS is a scale for quantifying disability in MS. Eight functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored on a scale from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is also scored. Based on scores in the 8 functional systems plus gait, an overall score ranging from 0 (normal) to 10 (death due to MS) in 0.5 unit increments is assigned. Participants with EDSS scores of 0.0 to 4.5 are fully ambulatory; patients with EDSS scores of 5.0 to 9.5 have impaired ambulation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.49" spread="1.158"/>
                    <measurement group_id="B2" value="2.48" spread="1.166"/>
                    <measurement group_id="B3" value="2.55" spread="1.145"/>
                    <measurement group_id="B4" value="2.51" spread="1.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EDSS Category</title>
          <description>The EDSS is a scale for quantifying disability in MS. Eight functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored on a scale of 0 (no disability) to 5 or 6 (more severe disability). Ambulation is also scored. Based on scores in these 8 functional systems and gait, an overall score ranging from 0 (normal) to 10 (death due to MS) in 0.5 unit increments is assigned. Participants with EDSS scores of 0.0 to 4.5 are fully ambulatory; patients with EDSS scores of 5.0 to 9.5 have impaired ambulation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>EDSS ≤ 3.5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="375"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="371"/>
                    <measurement group_id="B4" value="1120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>EDSS &gt; 3.5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Gadolinium-enhancing (GdE) Lesions</title>
          <description>A lesion appearing on magnetic resonance imagery (MRI), following injection of the chemical compound gadolinium, that reveals a breakdown in the blood-brain barrier. This breakdown of the blood-brain barrier indicates either a newly active lesion or the re-activation of an old one.</description>
          <population>Participants with available MRI data</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="440"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="433"/>
                    <count group_id="B4" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="3.54"/>
                    <measurement group_id="B2" value="1.8" spread="3.62"/>
                    <measurement group_id="B3" value="1.6" spread="3.78"/>
                    <measurement group_id="B4" value="1.7" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of T2 Lesions</title>
          <description>A T2-weighted MRI scan shows the number of old and new lesions in a specific part of the brain or spinal cord.</description>
          <population>Participants with available MRI data</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="440"/>
                    <count group_id="B2" value="439"/>
                    <count group_id="B3" value="432"/>
                    <count group_id="B4" value="1311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="32.62"/>
                    <measurement group_id="B2" value="48.7" spread="36.27"/>
                    <measurement group_id="B3" value="47.9" spread="32.37"/>
                    <measurement group_id="B4" value="48.4" spread="33.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normalized Brain Volume</title>
          <description>Measured using MRI</description>
          <population>Participants with available data</population>
          <units>cm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="439"/>
                    <count group_id="B2" value="437"/>
                    <count group_id="B3" value="432"/>
                    <count group_id="B4" value="1308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1449.581" spread="77.156"/>
                    <measurement group_id="B2" value="1452.852" spread="71.978"/>
                    <measurement group_id="B3" value="1441.949" spread="79.228"/>
                    <measurement group_id="B4" value="1448.153" spread="76.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Annualized Relapse Rate (ARR) at the End of Month 24</title>
        <description>A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for &gt; 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.&#xD;
Relapse rate was calculated as the total number of confirmed relapses divided by the total number of days in the study * 365.25.&#xD;
ARR was based on a Poisson regression model, adjusted for region (Eastern Europe vs Rest of the World), age, and the Baseline number of gadolinium-enhancing lesions, and included the natural log transformation of time on study as an offset term.</description>
        <time_frame>At the end of month 24</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study drug; participants were analyzed according to the treatment they were randomized to receive and not according to what they actually received, if different.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Annualized Relapse Rate (ARR) at the End of Month 24</title>
          <description>A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for &gt; 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.&#xD;
Relapse rate was calculated as the total number of confirmed relapses divided by the total number of days in the study * 365.25.&#xD;
ARR was based on a Poisson regression model, adjusted for region (Eastern Europe vs Rest of the World), age, and the Baseline number of gadolinium-enhancing lesions, and included the natural log transformation of time on study as an offset term.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study drug; participants were analyzed according to the treatment they were randomized to receive and not according to what they actually received, if different.</population>
          <units>relapses/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.276" lower_limit="0.234" upper_limit="0.324"/>
                    <measurement group_id="O2" value="0.218" lower_limit="0.183" upper_limit="0.259"/>
                    <measurement group_id="O3" value="0.172" lower_limit="0.142" upper_limit="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.025 level.</p_value_desc>
            <method>Poisson regression model</method>
            <method_desc>Adjusted for region, age, and Baseline number of GdE lesions, and Included the natural log transformation of time on study as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.623</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.506</ci_lower_limit>
            <ci_upper_limit>0.768</ci_upper_limit>
            <estimate_desc>Rate Ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0167</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.025 level.</p_value_desc>
            <method>Poisson Regression Model</method>
            <method_desc>Adjusted for region, age, and Baseline number of GdE lesions, and Included the natural log transformation of time on study as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.791</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.652</ci_lower_limit>
            <ci_upper_limit>0.958</ci_upper_limit>
            <estimate_desc>Rate Ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 24 Months</title>
        <description>The adjusted mean number of new or enlarging hyperintense T2-weighted brain MRI lesions per scan was based on the cumulative number of new or enlarging T2 lesions since Baseline over 24 months. MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.&#xD;
The adjusted mean per scan over 24 months was based based on a negative binomial regression model using observed data, adjusted for region (Eastern Europe vs. Rest of the World), age at Baseline, and Baseline number of GdE lesions. The natural log transformation of the number of available MRI scans over 24 months is used as an offset term.</description>
        <time_frame>24 month treatment period; MRI scans were performed at Months 12 and 24</time_frame>
        <population>ITT Population included all randomized participants who received at least 1 dose of study drug. Includes participants with non-missing MRI results.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 24 Months</title>
          <description>The adjusted mean number of new or enlarging hyperintense T2-weighted brain MRI lesions per scan was based on the cumulative number of new or enlarging T2 lesions since Baseline over 24 months. MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.&#xD;
The adjusted mean per scan over 24 months was based based on a negative binomial regression model using observed data, adjusted for region (Eastern Europe vs. Rest of the World), age at Baseline, and Baseline number of GdE lesions. The natural log transformation of the number of available MRI scans over 24 months is used as an offset term.</description>
          <population>ITT Population included all randomized participants who received at least 1 dose of study drug. Includes participants with non-missing MRI results.</population>
          <units>lesions/scan</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.183" lower_limit="2.640" upper_limit="3.838"/>
                    <measurement group_id="O2" value="2.092" lower_limit="1.741" upper_limit="2.514"/>
                    <measurement group_id="O3" value="1.835" lower_limit="1.523" upper_limit="2.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative Binomial Regression Model</method>
            <method_desc>Adjusted for region, age, and Baseline GdE lesions, and included the natural log transformation of available number of MRI scans as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.576</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.465</ci_lower_limit>
            <ci_upper_limit>0.714</ci_upper_limit>
            <estimate_desc>Rate Ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative binomial regression model</method>
            <method_desc>Adjusted for region, age, and Baseline GdE lesions and included the natural log transformation of available number of MRI scans as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.657</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.531</ci_lower_limit>
            <ci_upper_limit>0.813</ci_upper_limit>
            <estimate_desc>Rate Ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Number of Gadolinium Enhancing Brain Lesions at Month 24</title>
        <description>MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.&#xD;
The number of gadolinium-enhancing (GdE) lesions at 24 months was analyzed based on observed data using a negative binomial regression model adjusted for region (Eastern Europe vs Rest of World), Baseline age, and Baseline number of GdE lesions, with natural log transformation of number of available MRI scans over 24 months as an offset term (1 scan for per participant).</description>
        <time_frame>Month 24</time_frame>
        <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication. Includes participants with non-missing GdE MRI results at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Number of Gadolinium Enhancing Brain Lesions at Month 24</title>
          <description>MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.&#xD;
The number of gadolinium-enhancing (GdE) lesions at 24 months was analyzed based on observed data using a negative binomial regression model adjusted for region (Eastern Europe vs Rest of World), Baseline age, and Baseline number of GdE lesions, with natural log transformation of number of available MRI scans over 24 months as an offset term (1 scan for per participant).</description>
          <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication. Includes participants with non-missing GdE MRI results at Month 24.</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.373" lower_limit="0.256" upper_limit="0.543"/>
                    <measurement group_id="O2" value="0.197" lower_limit="0.131" upper_limit="0.296"/>
                    <measurement group_id="O3" value="0.176" lower_limit="0.116" upper_limit="0.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative Binomial Regression Model</method>
            <method_desc>Adjusted for region, age, and Baseline GdE lesions with the natural log transformation of available MRI scans at Month 24 as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.471</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.306</ci_lower_limit>
            <ci_upper_limit>0.725</ci_upper_limit>
            <estimate_desc>Rate ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0030</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative binomial regression model,</method>
            <method_desc>Adjusted for region, age, and Baseline GdE lesions with the natural log transformation of available MRI scans at Month 24 as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.528</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.346</ci_lower_limit>
            <ci_upper_limit>0.805</ci_upper_limit>
            <estimate_desc>Rate ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Disability Progression Confirmed After 3 Months</title>
        <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
        <time_frame>From first dose to the end of the 24-month treatment period</time_frame>
        <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Disability Progression Confirmed After 3 Months</title>
          <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
          <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8224</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Adjusted for region (Eastern Europe vs Rest of World) age at Baseline, and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.711</ci_lower_limit>
            <ci_upper_limit>1.537</ci_upper_limit>
            <estimate_desc>Hazard ratio (Ozanimod / IFN β-1a) based on Cox proportional hazard model with factors for treatment group, adjusted for region, age at Baseline, and Baseline EDSS score.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2849</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Adjusted for region (Eastern Europe vs Rest of World), age at Baseline, and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.798</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.528</ci_lower_limit>
            <ci_upper_limit>1.206</ci_upper_limit>
            <estimate_desc>Hazard ratio (Ozanimod / IFN β-1a) based on Cox proportional hazard model with factors for treatment group, adjusted for region, age at Baseline, and Baseline EDSS score.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Disability Progression Confirmed After 6 Months</title>
        <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
        <time_frame>From first dose to the end of the 24-month treatment period</time_frame>
        <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Disability Progression Confirmed After 6 Months</title>
          <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
          <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1353</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Cox proportional hazard model</method>
            <method_desc>Adjusted for region (Eastern Europe vs Rest of World), age at Baseline, and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.435</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.893</ci_lower_limit>
            <ci_upper_limit>2.305</ci_upper_limit>
            <estimate_desc>Hazard ratio (Ozanimod / IFN β-1a) based on Cox proportional hazard model with factors for treatment group, adjusted for region, age at Baseline, and Baseline EDSS score.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7154</p_value>
            <p_value_desc>To control for type 1 error, the key secondary endpoints were tested in order in a sequential, closed hierarchical testing procedure. Each comparison was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Cox proportional hazard model</method>
            <method_desc>Adjusted for region (Eastern Europe vs Rest of World), age at Baseline, and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.098</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.664</ci_lower_limit>
            <ci_upper_limit>1.815</ci_upper_limit>
            <estimate_desc>Hazard ratio (Ozanimod / IFN β-1a) based on Cox proportional hazard model with factors for treatment group, adjusted for region, age at Baseline, and Baseline EDSS score.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Gadolinium Enhancing (GdE) Lesion-Free at Month 24</title>
        <description>Participants were considered lesion free at Month 24 if they did not show evidence of GdE lesions at the Month 24 MRI scan.&#xD;
MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
        <time_frame>Month 24</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug; participants with missing data at Month 24 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Gadolinium Enhancing (GdE) Lesion-Free at Month 24</title>
          <description>Participants were considered lesion free at Month 24 if they did not show evidence of GdE lesions at the Month 24 MRI scan.&#xD;
MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug; participants with missing data at Month 24 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" lower_limit="51.6" upper_limit="60.9"/>
                    <measurement group_id="O2" value="63.3" lower_limit="58.8" upper_limit="67.8"/>
                    <measurement group_id="O3" value="65.6" lower_limit="61.1" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by region (Eastern Europe vs Rest of the World) and Baseline EDSS category</method_desc>
            <param_type>Difference</param_type>
            <param_value>9.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0320</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by region (Eastern Europe vs Rest of the World) and Baseline EDSS category</method_desc>
            <param_type>Difference</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were New or Enlarging T2 Lesion-Free at Month 24</title>
        <description>MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
        <time_frame>Month 24</time_frame>
        <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication; Participants with missing data at Month 24 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were New or Enlarging T2 Lesion-Free at Month 24</title>
          <description>MRI images were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
          <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication; Participants with missing data at Month 24 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="14.8" upper_limit="22.0"/>
                    <measurement group_id="O2" value="23.5" lower_limit="19.5" upper_limit="27.4"/>
                    <measurement group_id="O3" value="23.8" lower_limit="19.8" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0466</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on the Cochran-Mantel-Haenszel test stratified by region (Eastern Europe vs. rest of the world) and Baseline EDSS category</method_desc>
            <param_type>Difference</param_type>
            <param_value>5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0581</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on the Cochran-Mantel-Haenszel test stratified by region (Eastern Europe vs. rest of the world) and Baseline EDSS category</method_desc>
            <param_type>Difference</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Normalized Brain Volume to Month 24</title>
        <description>Brain volume (a measure of brain atrophy) was measured by brain MRI scans that were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population; last observation carried forward was used for participants with missing data at Month 24 (only post-baseline MRI scans were carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Normalized Brain Volume to Month 24</title>
          <description>Brain volume (a measure of brain atrophy) was measured by brain MRI scans that were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.</description>
          <population>ITT Population; last observation carried forward was used for participants with missing data at Month 24 (only post-baseline MRI scans were carried forward)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.937" spread="0.944"/>
                    <measurement group_id="O2" value="-0.707" spread="0.746"/>
                    <measurement group_id="O3" value="-0.707" spread="0.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on the analysis of covariance model, adjusted for region (Eastern Europe vs. rest of the world), Baseline EDSS category, and brain volume at Baseline</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in means</param_type>
            <param_value>0.244</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.363</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs. rest of the world), Baseline EDSS category, and brain volume at Baseline.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Based on the analysis of covariance model, adjusted for region (Eastern Europe vs. rest of the world), Baseline EDSS category, and brain volume at Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in means</param_type>
            <param_value>0.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.342</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs. rest of the world), Baseline EDSS category, and brain volume at Baseline.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 24 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test</title>
        <description>The MSFC-LCLA is a battery including the following 4 individual scales:&#xD;
Timed 25-Foot Walk is an ambulation measure of walking 25 feet with time taken recorded in seconds&#xD;
9-Hole Peg Test (9HPT) is a quantitative measure of upper extremity (arm and hand) function&#xD;
Symbol Digit Modalities Test (SDMT) is a measure of executive cognitive function that assesses processing speed, flexibility, and calculation ability&#xD;
Low-Contrast Letter Acuity Test (LCLA) used a standardized set of charts to assess low contrast visual acuity, charts are scored according to the number of letters that are identified correctly&#xD;
Z-scores were calculated for for each component and averaged to create an overall composite score, using the study population as the reference population. A Z-score represents the number of standard deviations a patient's test result is higher (Z &gt; 0) or lower (Z &lt; 0) than the average test result (Z = 0) of the reference population. A positive change indicates improvement.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>The ITT population with available MSFC Z-scores</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 24 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test</title>
          <description>The MSFC-LCLA is a battery including the following 4 individual scales:&#xD;
Timed 25-Foot Walk is an ambulation measure of walking 25 feet with time taken recorded in seconds&#xD;
9-Hole Peg Test (9HPT) is a quantitative measure of upper extremity (arm and hand) function&#xD;
Symbol Digit Modalities Test (SDMT) is a measure of executive cognitive function that assesses processing speed, flexibility, and calculation ability&#xD;
Low-Contrast Letter Acuity Test (LCLA) used a standardized set of charts to assess low contrast visual acuity, charts are scored according to the number of letters that are identified correctly&#xD;
Z-scores were calculated for for each component and averaged to create an overall composite score, using the study population as the reference population. A Z-score represents the number of standard deviations a patient's test result is higher (Z &gt; 0) or lower (Z &lt; 0) than the average test result (Z = 0) of the reference population. A positive change indicates improvement.</description>
          <population>The ITT population with available MSFC Z-scores</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="435"/>
                <count group_id="O3" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.052" spread="0.601"/>
                    <measurement group_id="O2" value="0.036" spread="0.440"/>
                    <measurement group_id="O3" value="-0.010" spread="0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2480</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on the analysis of covariance model, adjusted for region, Baseline EDSS category, and Baseline MSFC Z-score</method_desc>
            <param_type>Difference in means</param_type>
            <param_value>0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
            <estimate_desc>Difference in means are based on the analysis of covariance model, adjusted for region (Eastern Europe vs Rest of the World), Baseline EDSS category, and the Baseline MSFC Z-score.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0123</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on the analysis of covariance model, adjusted for region, Baseline EDSS category, and Baseline MSFC Z-score</method_desc>
            <param_type>Difference in means</param_type>
            <param_value>0.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.165</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs Rest of the World), Baseline EDSS category, and the Baseline MSFC Z-score.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores</title>
        <description>The MSQOL-54 is a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. The instrument includes 12 subscales, two summary scores, and two single-item measures.&#xD;
The two summary scores - physical health and mental health - are derived from a weighted combination of scale scores.&#xD;
The physical health composite score includes Physical function, Health perceptions, Energy/fatigue, Role limitations - physical, Pain, Sexual function, Social function, and Health distress.&#xD;
The mental health composite score includes Health distress, Overall quality of life, Emotional well-being, Role limitations - emotional, and Cognitive function.&#xD;
Each composite summary score has a range from 0 to 100 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication. Missing data were imputed using a mixed-effects regression model.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores</title>
          <description>The MSQOL-54 is a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. The instrument includes 12 subscales, two summary scores, and two single-item measures.&#xD;
The two summary scores - physical health and mental health - are derived from a weighted combination of scale scores.&#xD;
The physical health composite score includes Physical function, Health perceptions, Energy/fatigue, Role limitations - physical, Pain, Sexual function, Social function, and Health distress.&#xD;
The mental health composite score includes Health distress, Overall quality of life, Emotional well-being, Role limitations - emotional, and Cognitive function.&#xD;
Each composite summary score has a range from 0 to 100 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
          <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication. Missing data were imputed using a mixed-effects regression model.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Health Composite Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.526" spread="12.319"/>
                    <measurement group_id="O2" value="0.609" spread="12.315"/>
                    <measurement group_id="O3" value="0.209" spread="12.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Composite Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.831" spread="16.422"/>
                    <measurement group_id="O2" value="-1.182" spread="14.379"/>
                    <measurement group_id="O3" value="-1.517" spread="15.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of Physical Health Composite Summary Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0988</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on the analysis of covariance model, adjusted for region, Baseline EDSS category, and Baseline summary score</method_desc>
            <param_type>Difference in means</param_type>
            <param_value>1.345</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.252</ci_lower_limit>
            <ci_upper_limit>2.943</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs Rest of the World), Baseline EDSS category, and Baseline summary score.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Physical Health Composite Summary Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0228</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on the analysis of covariance model, adjusted for region, Baseline EDSS category, and Baseline summary score.</method_desc>
            <param_type>Difference in means</param_type>
            <param_value>1.849</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.258</ci_lower_limit>
            <ci_upper_limit>3.440</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs Rest of the World), Baseline EDSS category, and Baseline summary score.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of Mental Health Composite Summary Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6997</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on the analysis of covariance model, adjusted for region, Baseline EDSS category, and Baseline summary score</method_desc>
            <param_type>Difference in means</param_type>
            <param_value>0.380</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.553</ci_lower_limit>
            <ci_upper_limit>2.313</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs Rest of the World), Baseline EDSS category, and Baseline summary score.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Mental Health Composite Summary Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5501</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on the analysis of covariance model, adjusted for region, Baseline EDSS category, and the Baseline summary score</method_desc>
            <param_type>Difference in means</param_type>
            <param_value>0.587</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.339</ci_lower_limit>
            <ci_upper_limit>2.513</ci_upper_limit>
            <estimate_desc>Difference in means based on the analysis of covariance model, adjusted for region (Eastern Europe vs Rest of the World), Baseline EDSS category, and Baseline summary score.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events</title>
        <description>An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP), including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes.&#xD;
The investigator assessed the severity of AEs as mild, moderate, or severe and the relationship of each AE to treatment as unrelated, unlikely, possible, probable, or related based on timing and other known factors such as clinical state, environment, or other therapies.</description>
        <time_frame>From the first dose of study drug up to the first dose of the open-label extension study RPC01-3001, or up to 28 days after last dose for participants who did not continue into the open-label extension study; median duration of treatment was 24 months.</time_frame>
        <population>Safety Population included all participants who received at least 1 dose of study drug, analyzed according to the highest dose of ozanimod treatment actually received, not according to the treatment they were randomized to receive, if different.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events</title>
          <description>An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP), including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes.&#xD;
The investigator assessed the severity of AEs as mild, moderate, or severe and the relationship of each AE to treatment as unrelated, unlikely, possible, probable, or related based on timing and other known factors such as clinical state, environment, or other therapies.</description>
          <population>Safety Population included all participants who received at least 1 dose of study drug, analyzed according to the highest dose of ozanimod treatment actually received, not according to the treatment they were randomized to receive, if different.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="326"/>
                    <measurement group_id="O3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Moderate or Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Related Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to discontinuation of Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Study Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Death on Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent Change From Baseline in Normalized Brain Volume to Month 24 Based on Rank ANCOVA</title>
        <description>Brain volume (a measure of brain atrophy) was measured by brain MRI scans that were read at a centralized MRI reading facility by a blinded reader.&#xD;
Due to the non-normal distribution of the data for brain volume loss, the analyses for percent change from Baseline in normalized brain volume was repeated using rank-analysis of covariance (ANCOVA) and observed values.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population; participants with available data at Baseline and Month 24</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Normalized Brain Volume to Month 24 Based on Rank ANCOVA</title>
          <description>Brain volume (a measure of brain atrophy) was measured by brain MRI scans that were read at a centralized MRI reading facility by a blinded reader.&#xD;
Due to the non-normal distribution of the data for brain volume loss, the analyses for percent change from Baseline in normalized brain volume was repeated using rank-analysis of covariance (ANCOVA) and observed values.</description>
          <population>ITT Population; participants with available data at Baseline and Month 24</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.940" lower_limit="-5.33" upper_limit="1.44"/>
                    <measurement group_id="O2" value="-0.710" lower_limit="-5.21" upper_limit="1.36"/>
                    <measurement group_id="O3" value="-0.690" lower_limit="-5.65" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Rank ANCOVA</method>
            <method_desc>Adjusted for region and Baseline EDSS category, with the dependent variable as the residual of the rank of brain volume at Baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Rank ANCOVA</method>
            <method_desc>Adjusted for region and Baseline EDSS category, with the dependent variable as the residual of the rank of brain volume at Baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug to 28 days following the last dose of study drug; median duration of treatment was 24 months in each treatment group.</time_frame>
      <desc>The Safety Population included all participants who received at least 1 dose of study drug, analyzed according to the highest dose of ozanimod treatment actually received, not according to the treatment they were randomized to receive, if different.</desc>
      <group_list>
        <group group_id="E1">
          <title>Interferon Beta-1a</title>
          <description>Participants received IFN β-1a 30 µg intramuscular injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Ozanimod 0.5 mg</title>
          <description>Participants received ozanimod 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) weekly for 24 months.</description>
        </group>
        <group group_id="E3">
          <title>Ozanimod 1 mg</title>
          <description>Participants received ozanimod 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to interferon) weekly for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratoconus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Hyperplastic Cholecystopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Carbon Monoxide Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Comminuted Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Jaw Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Traumatic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Chronic Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Invasive Breast Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma In Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Medulloblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Ovarian Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Autonomic Nervous System Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Central Nervous System Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Cervical Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Generalised Tonic-Clonic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Speech Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Foetal Growth Restriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Placental Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Vanishing Twin Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="199" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="434"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one (1) year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene sixty (60) days prior to submission. Investigator must delete confidential information before submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email:</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

